342.99 USD
-1.58 (-0.46%)
Taking everything into account, AMGN scores 5 out of 10 in our fundamental rating. AMGN was compared to 533 industry peers in the Biotechnology industry. While AMGN belongs to the best of the industry regarding profitability, there are concerns on its financial health. AMGN has a correct valuation and a medium growth rate. Finally AMGN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
AMGN had positive earnings in the past year.
In the past year AMGN had a positive cash flow from operations.
In the past 5 years AMGN has always been profitable.
Each year in the past 5 years AMGN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.77%, AMGN belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
AMGN has a Return On Equity of 72.82%. This is amongst the best in the industry. AMGN outperforms 99.06% of its industry peers.
AMGN has a better Return On Invested Capital (15.39%) than 95.87% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMGN is significantly below the industry average of 18.83%.
The last Return On Invested Capital (15.39%) for AMGN is above the 3 year average (13.04%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROIC | 15.39% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
1.3 Margins
Looking at the Profit Margin, with a value of 19.47%, AMGN belongs to the top of the industry, outperforming 94.00% of the companies in the same industry.
AMGN's Profit Margin has declined in the last couple of years.
AMGN's Operating Margin of 33.57% is amongst the best of the industry. AMGN outperforms 97.19% of its industry peers.
In the last couple of years the Operating Margin of AMGN has declined.
The Gross Margin of AMGN (72.06%) is better than 82.18% of its industry peers.
In the last couple of years the Gross Margin of AMGN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% |
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
AMGN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for AMGN has been increased compared to 1 year ago.
The number of shares outstanding for AMGN has been reduced compared to 5 years ago.
Compared to 1 year ago, AMGN has an improved debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of AMGN is 4.28, which is a neutral value as it means it would take AMGN, 4.28 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 4.28, AMGN belongs to the best of the industry, outperforming 91.93% of the companies in the same industry.
AMGN has a Debt/Equity ratio of 5.45. This is a high value indicating a heavy dependency on external financing.
AMGN's Debt to Equity ratio of 5.45 is on the low side compared to the rest of the industry. AMGN is outperformed by 82.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Altman-Z | N/A |
ROIC/WACC1.81
WACC8.49%
2.3 Liquidity
A Current Ratio of 1.28 indicates that AMGN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.28, AMGN is doing worse than 84.05% of the companies in the same industry.
A Quick Ratio of 0.99 indicates that AMGN may have some problems paying its short term obligations.
AMGN has a worse Quick ratio (0.99) than 86.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.79% over the past year.
The Earnings Per Share has been growing slightly by 5.97% on average over the past years.
AMGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.56%.
Measured over the past years, AMGN shows a small growth in Revenue. The Revenue has been growing by 7.43% on average per year.
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
3.2 Future
The Earnings Per Share is expected to grow by 4.18% on average over the next years.
AMGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.22% yearly.
EPS Next Y8.22%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
EPS Next 5Y4.18%
Revenue Next Year7.43%
Revenue Next 2Y4.6%
Revenue Next 3Y3.97%
Revenue Next 5Y3.22%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 15.68 indicates a correct valuation of AMGN.
Compared to the rest of the industry, the Price/Earnings ratio of AMGN indicates a rather cheap valuation: AMGN is cheaper than 95.31% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of AMGN to the average of the S&P500 Index (26.15), we can say AMGN is valued slightly cheaper.
A Price/Forward Earnings ratio of 15.59 indicates a correct valuation of AMGN.
Based on the Price/Forward Earnings ratio, AMGN is valued cheaply inside the industry as 95.87% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of AMGN to the average of the S&P500 Index (36.12), we can say AMGN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.68 | ||
| Fwd PE | 15.59 |
4.2 Price Multiples
AMGN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMGN is cheaper than 95.50% of the companies in the same industry.
AMGN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMGN is cheaper than 96.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.48 | ||
| EV/EBITDA | 13.06 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AMGN does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of AMGN may justify a higher PE ratio.
PEG (NY)1.91
PEG (5Y)2.63
EPS Next 2Y5.36%
EPS Next 3Y4.87%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.83%, AMGN has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 74.20, AMGN pays a better dividend. On top of this AMGN pays more dividend than 98.69% of the companies listed in the same industry.
AMGN's Dividend Yield is comparable with the S&P500 average which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.83% |
5.2 History
The dividend of AMGN is nicely growing with an annual growth rate of 9.41%!
AMGN has been paying a dividend for at least 10 years, so it has a reliable track record.
AMGN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)9.41%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
AMGN pays out 17.20% of its income as dividend. This is a sustainable payout ratio.
AMGN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP17.2%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
NASDAQ:AMGN (11/28/2025, 10:03:06 AM)
342.99
-1.58 (-0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.15%
Inst Owner Change-3.55%
Ins Owners0.06%
Ins Owner Change-0.85%
Market Cap184.65B
Revenue(TTM)35.97B
Net Income(TTM)7.00B
Analysts72
Price Target327.38 (-4.55%)
Short Float %2.5%
Short Ratio5.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.83% |
Yearly Dividend9.01
Dividend Growth(5Y)9.41%
DP17.2%
Div Incr Years13
Div Non Decr Years13
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.96%
Min EPS beat(2)10.28%
Max EPS beat(2)11.64%
EPS beat(4)4
Avg EPS beat(4)9.04%
Min EPS beat(4)2.49%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)5.13%
EPS beat(12)10
Avg EPS beat(12)4.44%
EPS beat(16)14
Avg EPS beat(16)4.21%
Revenue beat(2)2
Avg Revenue beat(2)2.59%
Min Revenue beat(2)0.68%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.17%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.21%
Revenue beat(12)4
Avg Revenue beat(12)-0.48%
Revenue beat(16)5
Avg Revenue beat(16)-0.54%
PT rev (1m)2.32%
PT rev (3m)2.42%
EPS NQ rev (1m)-7.42%
EPS NQ rev (3m)-7.94%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)-0.32%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)1.12%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.68 | ||
| Fwd PE | 15.59 | ||
| P/S | 5.13 | ||
| P/FCF | 14.48 | ||
| P/OCF | 14.07 | ||
| P/B | 19.2 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.06 |
EPS(TTM)21.87
EY6.38%
EPS(NY)22
Fwd EY6.41%
FCF(TTM)23.69
FCFY6.91%
OCF(TTM)24.38
OCFY7.11%
SpS66.82
BVpS17.87
TBVpS-59.8
PEG (NY)1.91
PEG (5Y)2.63
Graham Number93.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROCE | 17.67% | ||
| ROIC | 15.39% | ||
| ROICexc | 17.86% | ||
| ROICexgc | 61.56% | ||
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% | ||
| FCFM | 35.46% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
ROICexc(3y)15.77%
ROICexc(5y)17.27%
ROICexgc(3y)75.76%
ROICexgc(5y)77.1%
ROCE(3y)14.97%
ROCE(5y)16.28%
ROICexgc growth 3Y3.26%
ROICexgc growth 5Y-18.2%
ROICexc growth 3Y-8.67%
ROICexc growth 5Y-7.85%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
F-Score7
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Debt/EBITDA | 2.97 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.3% | ||
| Profit Quality | 182.08% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | N/A |
F-Score7
WACC8.49%
ROIC/WACC1.81
Cap/Depr(3y)24.77%
Cap/Depr(5y)23.42%
Cap/Sales(3y)3.59%
Cap/Sales(5y)3.31%
Profit Quality(3y)165.92%
Profit Quality(5y)155.23%
High Growth Momentum
Growth
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
EPS Next Y8.22%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
EPS Next 5Y4.18%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
Revenue Next Year7.43%
Revenue Next 2Y4.6%
Revenue Next 3Y3.97%
Revenue Next 5Y3.22%
EBIT growth 1Y93.73%
EBIT growth 3Y1.84%
EBIT growth 5Y-0.13%
EBIT Next Year39.98%
EBIT Next 3Y10.33%
EBIT Next 5Y7.12%
FCF growth 1Y36%
FCF growth 3Y7.44%
FCF growth 5Y4.03%
OCF growth 1Y24.04%
OCF growth 3Y7.45%
OCF growth 5Y4.66%
AMGEN INC / AMGN FAQ
Can you provide the ChartMill fundamental rating for AMGEN INC?
ChartMill assigns a fundamental rating of 5 / 10 to AMGN.
Can you provide the valuation status for AMGEN INC?
ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.
What is the profitability of AMGN stock?
AMGEN INC (AMGN) has a profitability rating of 7 / 10.
What are the PE and PB ratios of AMGEN INC (AMGN) stock?
The Price/Earnings (PE) ratio for AMGEN INC (AMGN) is 15.68 and the Price/Book (PB) ratio is 19.2.
What is the financial health of AMGEN INC (AMGN) stock?
The financial health rating of AMGEN INC (AMGN) is 3 / 10.